CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals)

Drug Alias NameCD19 CAR engineered autologous T-cells

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia, Biphenotypic, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSabz Biomedicals

China Registration ClassN/A

Develop Information

Active CompaniesSabz Biomedicals

Inactive CompaniesN/A

Active IndicationsLeukemia, Biphenotypic, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A